173 related articles for article (PubMed ID: 9811046)
41. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.
Maradit-Kremers H; Nicola PJ; Crowson CS; O'Fallon WM; Gabriel SE
J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365
[TBL] [Abstract][Full Text] [Related]
42. Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis.
Turesson C; O'Fallon WM; Crowson CS; Gabriel SE; Matteson EL
J Rheumatol; 2002 Jan; 29(1):62-7. PubMed ID: 11824973
[TBL] [Abstract][Full Text] [Related]
43. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis.
Krause D; Schleusser B; Herborn G; Rau R
Arthritis Rheum; 2000 Jan; 43(1):14-21. PubMed ID: 10643695
[TBL] [Abstract][Full Text] [Related]
44. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.
Seong SS; Choi CB; Woo JH; Bae KW; Joung CL; Uhm WS; Kim TH; Jun JB; Yoo DH; Lee JT; Bae SC
J Rheumatol; 2007 Apr; 34(4):706-11. PubMed ID: 17309133
[TBL] [Abstract][Full Text] [Related]
45. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden.
Askling J; Fored CM; Brandt L; Baecklund E; Bertilsson L; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Romanus V; Klareskog L; Feltelius N
Arthritis Rheum; 2005 Jul; 52(7):1986-92. PubMed ID: 15986370
[TBL] [Abstract][Full Text] [Related]
46. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors.
Chakravarty EF; Michaud K; Wolfe F
J Rheumatol; 2005 Nov; 32(11):2130-5. PubMed ID: 16265690
[TBL] [Abstract][Full Text] [Related]
47. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis.
Prodanovich S; Ma F; Taylor JR; Pezon C; Fasihi T; Kirsner RS
J Am Acad Dermatol; 2005 Feb; 52(2):262-7. PubMed ID: 15692471
[TBL] [Abstract][Full Text] [Related]
48. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis.
Setoguchi S; Solomon DH; Weinblatt ME; Katz JN; Avorn J; Glynn RJ; Cook EF; Carney G; Schneeweiss S
Arthritis Rheum; 2006 Sep; 54(9):2757-64. PubMed ID: 16947774
[TBL] [Abstract][Full Text] [Related]
49. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study.
Davis JM; Maradit Kremers H; Crowson CS; Nicola PJ; Ballman KV; Therneau TM; Roger VL; Gabriel SE
Arthritis Rheum; 2007 Mar; 56(3):820-30. PubMed ID: 17330254
[TBL] [Abstract][Full Text] [Related]
50. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis.
Panoulas VF; Douglas KM; Milionis HJ; Stavropoulos-Kalinglou A; Nightingale P; Kita MD; Tselios AL; Metsios GS; Elisaf MS; Kitas GD
Rheumatology (Oxford); 2007 Sep; 46(9):1477-82. PubMed ID: 17704521
[TBL] [Abstract][Full Text] [Related]
51. Coffee, tea, and caffeine consumption and risk of rheumatoid arthritis: results from the Iowa Women's Health Study.
Mikuls TR; Cerhan JR; Criswell LA; Merlino L; Mudano AS; Burma M; Folsom AR; Saag KG
Arthritis Rheum; 2002 Jan; 46(1):83-91. PubMed ID: 11817612
[TBL] [Abstract][Full Text] [Related]
52. Mortality in rheumatoid arthritis patients treated with or without methotrexate.
Singer RB
J Insur Med; 2003; 35(3-4):144-9. PubMed ID: 14971085
[TBL] [Abstract][Full Text] [Related]
53. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years.
Gabriel SE; Crowson CS; Kremers HM; Doran MF; Turesson C; O'Fallon WM; Matteson EL
Arthritis Rheum; 2003 Jan; 48(1):54-8. PubMed ID: 12528103
[TBL] [Abstract][Full Text] [Related]
54. Variable cyclosporine exposure: a risk factor for chronic allograft nephropathy and graft loss?
He X; Johnston A
Transplant Proc; 2004 Jun; 36(5):1321-6. PubMed ID: 15251323
[TBL] [Abstract][Full Text] [Related]
55. Death rates and causes of death in patients with rheumatoid arthritis: a population-based study.
Sihvonen S; Korpela M; Laippala P; Mustonen J; Pasternack A
Scand J Rheumatol; 2004; 33(4):221-7. PubMed ID: 15370716
[TBL] [Abstract][Full Text] [Related]
56. The risk of lymphoma development in autoimmune diseases: a meta-analysis.
Zintzaras E; Voulgarelis M; Moutsopoulos HM
Arch Intern Med; 2005 Nov; 165(20):2337-44. PubMed ID: 16287762
[TBL] [Abstract][Full Text] [Related]
57. Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis.
Bernatsky S; Hudson M; Suissa S
Rheumatology (Oxford); 2005 May; 44(5):677-80. PubMed ID: 15784627
[TBL] [Abstract][Full Text] [Related]
58. Declines in mortality from acute myocardial infarction in successive incidence and birth cohorts of patients with rheumatoid arthritis.
Krishnan E; Lingala VB; Singh G
Circulation; 2004 Sep; 110(13):1774-9. PubMed ID: 15381644
[TBL] [Abstract][Full Text] [Related]
59. The widening mortality gap between rheumatoid arthritis patients and the general population.
Gonzalez A; Maradit Kremers H; Crowson CS; Nicola PJ; Davis JM; Therneau TM; Roger VL; Gabriel SE
Arthritis Rheum; 2007 Nov; 56(11):3583-7. PubMed ID: 17968923
[TBL] [Abstract][Full Text] [Related]
60. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis.
Jacobsson LT; Turesson C; Gülfe A; Kapetanovic MC; Petersson IF; Saxne T; Geborek P
J Rheumatol; 2005 Jul; 32(7):1213-8. PubMed ID: 15996054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
